Page last updated: 2024-08-24

rubitecan and Myelodysplastic Syndromes

rubitecan has been researched along with Myelodysplastic Syndromes in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cortes, J; Faderl, S; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S; Pierce, S; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S	1

Trials

1 trial(s) available for rubitecan and Myelodysplastic Syndromes

Article	Year
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer, 2006, Oct-01, Volume: 107, Issue:7 Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Topoisomerase I Inhibitors; Treatment Outcome	2006

Article

Year

Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.

Cancer, 2006, Oct-01, Volume: 107, Issue:7

Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Camptothecin; Female; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Topoisomerase I Inhibitors; Treatment Outcome

2006